Turning Point Therapeutics Inc. (TPTX) PT Lowered to $186 at H.C. Wainwright
H.C. Wainwright analyst Raghuam Selvaraju lowered the price target on Turning Point Therapeutics Inc. (NASDAQ: TPTX) to $186.00 (from $190.00) while maintaining a Buy rating.
You May Also Be Interested In
- FirstRand Ltd. (FSR:SJ) (FANDF) PT Raised to ZAR73 at HSBC
- Sigma Healthcare Ltd. (SIG:AU) PT Lowered to AUD0.70 at Credit Suisse
- Severn Trent Plc. (SVT:LN) (SVTRF) PT Lowered to GBP30 at HSBC
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!